Abstract: The present invention relates to a method of producing sesquiterpene lactones of the thapsigargin family, the method comprising the steps of: (a) culturing plant cells of the genus Thapsia in a nutrient medium in a suspension cell culture, wherein the cells produce one or more sesquiterpene lactones of the thapsigargin family; and (b) recovering one or more sesquiterpene lactones of the thapsigargin family produced in (a). The present invention further relates to a suspension cell culture comprising plant cells of the genus Thapsia, wherein the plant cells are capable of producing one or more sesquiterpene lactones of the thapsigargin family and to a plant cell biomass comprising plant cells of the genus Thapsia obtained from said suspension cell culture.

Abstract: The present invention relates to a method of producing Ingenol, Ingenol esters and/or Tiglian-3-one derivatives, the method comprising the steps of: (a) culturing plant cells obtained from a plant selected from the family Euphorbiaceae in a nutrient medium in a suspension cell culture, wherein the cells produce Ingenol, one or more Ingenol esters and/or one or more Tiglian-3-one derivatives; and (b) recovering the Ingenol, the one or more Ingenol esters and/or the one or more Tiglian-3-one derivatives produced in (a). The present invention further relates to a plant suspension cell culture, wherein the cells are obtained from a plant selected from the family Euphorbiaceae, and wherein the plant cells produce Ingenol and/or one or more Ingenol ester and/or one or more Tiglian-3-one derivatives.

Abstract: The present invention relates to a method of producing Ingenol, Ingenol esters and/or Tiglian-3-one derivatives, the method comprising the steps of: (a) culturing plant cells obtained from a plant selected from the family Euphorbiaceae in a nutrient medium in a suspension cell culture, wherein the cells produce Ingenol, one or more Ingenol esters and/or one or more Tiglian-3-one derivatives; and (b) recovering the Ingenol, the one or more Ingenol esters and/or the one or more Tiglian-3-one derivatives produced in (a). The present invention further relates to a plant suspension cell culture, wherein the cells are obtained from a plant selected from the family Euphorbiaceae, and wherein the plant cells produce Ingenol and/or one or more Ingenol ester and/or one or more Tiglian-3-one derivatives.

Abstract: The present invention relates to a method of producing sesquiterpene lactones of the thapsigargin family, the method comprising the steps of: (a) culturing plant cells of the genus Thapsia in a nutrient medium in a suspension cell culture, wherein the cells produce one or more sesquiterpene lactones of the thapsigargin family; and (b) recovering one or more sesquiterpene lactones of the thapsigargin family produced in (a). The present invention further relates to a suspension cell culture comprising plant cells of the genus Thapsia, wherein the plant cells are capable of producing one or more sesquiterpene lactones of the thapsigargin family and to a plant cell biomass comprising plant cells of the genus Thapsia obtained from said suspension cell culture.

Abstract: The invention is directed to a method for the production of taxanes by culturing suspension cells of Taxus sp. in a nutrient medium that comprises an indanoyl amino acid. The indanoyl amino acid may be added in batch mode or in a feed stream at any time of the culturing. In particular, synthetic compounds 6-Ethyl-indanoyl-isoleucine, 6-Bromoindanoyl isoleucine and 1-oxo-indane-carboxy-(L)-Isoleucine-methyl ester amide (1-OII) have been found to increase taxane production from Taxus cell cultures.

Abstract: A blister pack unit for a powder inhaler, comprising a body which includes a plurality of surfaces which each includes a plurality of blisters (21, 22) containing powder containing medicament and are rotationally symmetrically disposed about an imaginary axis.

Abstract: The invention provides a pharmaceutical composition for rectal or vaginal administration which comprises at least two parts wherein the composition comprises (i) two or more physiologically acceptable substances each in separate parts of the composition which are such that on admixture they react to produce a physiologically acceptable gas; (ii) in at least one part of the composition a polymer stabiliser which is adapted to facilitate the formation of a water-soluble collapsible foam structure; and (iii) in at least one part of the composition a pharmaceutically active substance; an its use in the treatment or prophylaxis of disorders of the intestines, rectum or vagina.

Abstract: The invention provides a unit formulation which comprises a 2-hydroxy-5-phenylazobenzoic acid derivative which is particularly sodium balsalazide dihydrate which formulation has a density of at least 0.9 mg/mm3 and its use in the treatment of gastrointestinal diseases.

Abstract: Cholestyramine and starch containing, oil-free compositions with excellent organoleptic features are obtained by mixing cholestyramine and grain starch in a weight ratio of 1:1.8 to 2.9 with the addition of grain bran as a filler and optionally an aroma stuff with 10 to 35% by weight of water (calc. on the starting materials) into a homogenous moist mass, forming of the mass through extrusion into a string, whereby the temperature is 105.degree.-180.degree. C. (measured in the mass in the extrusion head) and the pressure is 30-70 bars (measured in the extrusion head), and subsequently drying at a temperature above 100.degree. C. to a remaining humidity of .ltoreq.3.5% by weight, whereby the extruded material before or after the drying is divided into bars or is grinded into a powder.

Abstract: A device for carrying out urease tests for combined antrum/corpus biopsies to diagnose gastro-intestinal illnesses has a carrier plate, a schematic representation of the stomach on the plate, at least one opening in the plate at the locations corresponding to the corpus and the antrum in the schematic representation of the stomach, an evaluation scale for assessment of the urease test and an area for data on the patient and for clinical data.

Abstract: A pharmaceutical composition having a form suitable for transmucosal administration containing progesterone and/or 17-.beta.-estradiol as an active ingredient.